PARSIPPANY, N.J.--(BUSINESS WIRE)--Ferring Pharmaceuticals and its clinical development partner, Seikagaku Corporation (Seikagaku), today announced the presentation of two analyses of data at the American Society of Pain and Neuroscience (ASPN) 2024 Annual Meeting, for SI-6603, an investigational therapy intended to treat radicular leg pain associated with lumbar disc herniation (LDH). The congress will take place July 11-24, 2024, in Miami, FL.
The poster presentations include an evaluation of early treatment response to SI-6603 from the completed United States Phase 3 Discovery 6603 clinical trial, and an analysis of LDH-related healthcare resource utilization (HRU) and costs for patients with LDH who underwent surgical procedures.
The abstracts accepted for presentation are as follows:
Poster #44 Title– Early Response of SI-6603 (condoliase) for Lumbar Disc Herniation Associated With Radicular Leg Pain
Presenting Author: Timothy R. Deer, MD, DABPM, Clinical Professor of Anaesthesiology, West Virginia University School of Medicine, President & Chief Executive Officer, The Spine and Nerve Centers of the Virginias and the Center for Pain Relief, Inc.
EMBARGOED UNTIL: Monday, July 15, 2024, at 8:00 a.m. ET
Poster #171 Title– Healthcare Resource Utilization and Costs associated with Lumbar Disc Herniation Surgery in the United States
Presenting Author: Kinsuk Chauhan, MD, MPH, Senior Manager of Real World Evidence and Health Economics Outcomes Research Ferring Pharmaceuticals
EMBARGOED UNTIL: Monday, July 15, 2024, at 8:00 a.m. ET
About Lumbar Disc Herniation
About 9 million adults in the U.S. suffer from lumbar disc herniation each year. A disc herniation is a displacement of the gel-like inner core of the intervertebral disc, called the nucleus pulposus, through its external membrane (annulus fibrosus) due to wear and tear, aging or sudden injury. As a result of this displacement, the disc presses on the spinal nerve, often producing pain.1,2
About SI-6603
SI-6603, which contains condoliase as its active pharmaceutical ingredient, is an investigational product intended to treat radicular leg pain associated with lumbar disc herniation via a single, direct intradiscal injection.
SI-6603 was developed by Seikagaku. Marketing approval for SI-6603 in Japan was obtained from the Japanese Ministry of Health, Labour and Welfare in March 2018 and SI-6603 has been marketed in Japan only as HERNICORE® 1.25 units for intradiscal injection through Seikagaku Corporation’s Japanese sales partner Kaken Pharmaceutical Co., Ltd. (Tokyo, Japan) since August 1, 2018.3
Alliance with Seikagaku
Seikagaku and Ferring entered into a license agreement for SI-6603 in August 2016. Ferring plans to commercialize the product in the United States and has received further rights to develop, register and commercialize SI-6603 worldwide, excluding Japan.
About Ferring Pharmaceuticals
Ferring Pharmaceuticals is a privately-owned, research-driven, specialty biopharmaceutical group committed to building families and helping people live better lives. In the United States, Ferring is a leader in reproductive medicine and maternal health, and in areas of gastroenterology and orthopaedics. We are at the forefront of innovation in microbiome-based therapeutics and uro-oncology intravesical gene therapy. Our company was founded in 1950 and is headquartered in Saint-Prex, Switzerland. Ferring employs more than 7,000 people worldwide and markets its medicines in over 100 countries. Ferring USA is based in Parsippany, New Jersey, and employs more than 900 employees.
For more information, please visit www.ferringusa.com, call 1-888-FERRING (1-888-337-7464), or connect with us on LinkedIn and X (Twitter).
References:
1 Vialle LR, Vialle EN, Suárez Henao JE, Giraldo G. Lumbar Disc Herniation. Rev Bras Ortop. 2015 Nov 16;45(1):17-22. doi: 10.1016/S2255-4971(15)30211-1. PMID: 27019834; PMCID: PMC4799068.
2 Herniated Disk in the Lower Back. OrthoInfo. American Academy of Orthopaedic Surgeons. Available at: https://orthoinfo.aaos.org/en/diseases--conditions/herniated-disk-in-the-lower-back/. Accessed May 23, 2023.
3 Press Release. Seikagaku and Kaken Announce the Launch of HERNICORE® 1.25 Units for Intradiscal Injection in Japan. July 31, 2018. Available at: https://www.seikagaku.co.jp/en/news/news-6617037418084939174/main/0/link/20180731-e.pdf. Accessed May 24, 2023.
